Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor

metastasis
epidermal growth factor
HER2
luteinizing hormone
palbociclib
  • 0 views
  • 22 Mar, 2022
  • 1 location
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer (EUTACAM)

This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and

breast cancer staging
tamoxifen
hormone therapy
  • 0 views
  • 24 Apr, 2022
  • 1 location
Endocrine Response in Women With Invasive Lobular Breast Cancer

RATIONALE: Currently, adjuvant endocrine therapy often follows a "one-size-fits- all" approach, with most premenopausal women receiving tamoxifen, and most postmenopausal receiving aromatase

HER2
core needle biopsy
endocrine therapy
immunostimulant
adjuvant therapy
  • 127 views
  • 22 Apr, 2022
  • 10 locations
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

having received chemotherapy). Following the Screening Period, eligible subjects will enter into the 48 week Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506

HER2
her2/neu-negative breast cancer
adjuvant chemotherapy
erbb2
exemestane
  • 0 views
  • 29 May, 2022
  • 21 locations
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen

metastasis
HER2
immunological adjuvant
palbociclib
alopecia
  • 1 views
  • 02 Mar, 2022
  • 3 locations
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.

  • 0 views
  • 30 May, 2022
  • 3 locations
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE)

. Antihormone therapy, such as fulvestrant, letrozole, anastrozole, exemestane, or tamoxifen, may lessen the amount of estrogen made by the body. Giving radiation therapy, palbociclib, and hormone therapy may

  • 18 views
  • 09 Feb, 2022
  • 10 locations
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ (HORNEO01)

after hormone therapy. Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence. The HORNEO 01 trial

estrogen receptor
mastectomy
hormone therapy
estrogen
tamoxifen
  • 0 views
  • 01 May, 2022
  • 7 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

(HER2-E), HR+/HER2-negative breast cancer who had recurrence or progression while receiving previous ET (either aromatase inhibitors, tamoxifen or fulvestrant) in the adjuvant setting or to treat

metastasis
HER2
core needle biopsy
endocrine therapy
her2/neu-negative breast cancer
  • 0 views
  • 02 Aug, 2021
  • 15 locations
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made

HER2
bisphosphonates
epidermal growth factor receptor
endocrine therapy
human epidermal growth factor receptor 2
  • 0 views
  • 22 Mar, 2022
  • 1 location